Intraventricular Rituximab in Pediatric CD20-positive Refractory Primary Central Nervous System Lymphoma

被引：2

作者：

Wada-Shimosato, Yuko ^{[1
]}

Ikeda, Junji ^{[1
]}

Tsujimoto, Shin-ichi ^{[1
]}

Sasaki, Koji ^{[1
]}

Yanagimachi, Masakatsu ^{[1
]}

Kajiwara, Ryosuke ^{[1
]}

Shiba, Norio ^{[1
]}

Murata, Hidetoshi ^{[2
]}

Kawahara, Nobutaka ^{[2
]}

Yamanaka, Shoji ^{[3
]}

Tanoshima, Reo ^{[1
]}

Ito, Shuichi ^{[1
]}

机构：

[1] Yokohama City Univ, Sch Med, Dept Pediat, Yokohama, Kanagawa, Japan

[2] Yokohama City Univ, Sch Med, Dept Neurosurg, Yokohama, Kanagawa, Japan

[3] Yokohama City Univ, Sch Med, Dept Pathol, Yokohama, Kanagawa, Japan

来源：

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY | 2019年 / 41卷 / 07期

基金：

日本学术振兴会;

关键词：

primary central nervous system lymphoma; intraventricular rituximab; non-Hodgkin lymphoma; CD20; MANAGEMENT; RADIATION; CHILDREN; THERAPY; TRIAL; BRAIN;

D O I：

10.1097/MPH.0000000000001291

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Primary central nervous system lymphoma (PCNSL) is a rare and aggressive type of extranodal non-Hodgkin lymphoma that carries an unsatisfactory prognosis. Treating refractory PCNSL is challenging because of resistance to conventional cytotoxic and intrathecal chemotherapies. Therefore, novel therapeutic approaches are needed. Here, we report a 12-year-old boy with CD20-positive PCNSL, which was refractory to combination chemotherapy and intravenous rituximab. However, the patient achieved complete remission after repeated intraventricular rituximab administration. The results of this case indicate that intraventricular rituximab is an effective option to treat refractory PCNSL in children.

引用

页码：571 / 573

页数：3

共 50 条

[21] Primary intraventricular central nervous system lymphoma in an immunocompetent patient
Suri, Vinit
Mittapalli, Venkatesh
Kulshrestha, Manish
Premlani, Kaushal
Sogani, S. K.
Suri, Kunal
[J]. JOURNAL OF PEDIATRIC NEUROSCIENCES, 2015, 10 (04) : 393 - 395
[22] Complement Activation and Intraventricular Rituximab Distribution in Recurrent Central Nervous System Lymphoma
Kadoch, Cigall
Li, Jing
Wong, Valerie S.
Chen, Lingjing
Cha, Soonmee
Munster, Pamela
Lowell, Clifford A.
Shuman, Marc A.
Rubenstein, James L.
[J]. CLINICAL CANCER RESEARCH, 2014, 20 (04) : 1029 - 1041
[23] Reply to ‘Rituximab activity in CD20-positive multiple myeloma’
A Gozzetti
A Fabbri
S Lazzi
M Bocchia
F Lauria
[J]. Leukemia, 2008, 22 : 1083 - 1083
[24] PEMETREXED FOR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Rauschkolb, Paula K.
Drappatz, Jan
Batchelor, Tracy T.
Meyer, Louise P.
Fadul, Camilo E.
Lallana, Enrico C.
[J]. NEURO-ONCOLOGY, 2010, 12 : 54 - 54
[25] Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells
Luo, Chengke
Deng, Zhenghao
Li, Lan
Clayton, Frederic
Chen, Alexander L.
Wei, Ran
Miles, Rodney
Stephens, Deborah M.
Glenn, Martha
Wang, Xiyang
Jensen, Peter E.
Chen, Xinjian
[J]. ONCOTARGET, 2016, 7 (11) : 12806 - 12822
[26] Reply to 'Rituximab activity in CD20-positive multiple myeloma'
Bergua, J. M.
Cabrera, C.
Arteta, E. G.
Prieto, J.
[J]. LEUKEMIA, 2008, 22 (05) : 1083 - 1084
[27] The Role of Rituximab in the Treatment of Primary Central Nervous System Lymphoma
Van Dijck, Ruben
Doorduijn, Jeanette K.
Bromberg, Jacoline E. C.
[J]. CANCERS, 2021, 13 (08)
[28] Lateral intraventricular primary central nervous system lymphoma (LIPCNSL): a review
Yang, J.
Liu, Z.
Yang, Y.
Chen, H.
Xu, J.
[J]. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2020, 113 (07) : 457 - 464
[29] A case of CD20-positive peripheral T-cell lymphoma treated with rituximab and multiagent chemotherapy
Kamata, Masahiro
Sugaya, Makoto
Miyagaki, Tomomitsu
Sonoda, Koya
Ichimura, Yohei
Mitsui, Hiroshi
Sato, Shinichi
Kamikubo, Yasuhiko
Kurokawa, Mineo
[J]. INTERNATIONAL JOURNAL OF DERMATOLOGY, 2014, 53 (01) : E24 - E26
[30] Primary CD20-positive mediastinal diffuse large B-cell lymphoma
Rajabto, Wulyo
Priantono, Dimas
[J]. RESPIROLOGY CASE REPORTS, 2020, 8 (08):

← 1 2 3 4 5 →